ENO2 and lung cancer: In particular, panel 1, consisting of 4 TAAs (CYFR21, CEA, NSE, and SCC), panel 2, consisting of 6 TAAs (CYFR21, CEA, NSE, SCC, CA125, and CA15-3), and panel 4, consisting of 10 TAAs (CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724), showed improved diagnostic efficacy in different types of lung cancer patients.